VS-7375

Biomarkers

Sponsors

Industry sponsors leading active biomarker-selected trials of VS-7375.

1. Genfleet Therapeutics 5
2. Verastem 4

Trials

9 of 10 trials shown

1. A Study to Evaluate GFH375 Versus Docetaxel in Participants With Non-Small Cell Lung Cancer With KRAS G12D Mutation

   Recruiting Phase 3 Genfleet Therapeutics Started 2026Primary completion 2030-06 NCT07668752

   VS-7375docetaxel

   …e to undergo tumor biopsy to obtain tissue samples for central laboratory confirmation of KRAS G12D mutation.

   KRAS G12DKRAS G12D Mutation, NSCLC (Non-small Cell Lung Cancer)

2. A Phase 2 Study of VS-7375 in Patients With KRAS G12D-Mutated Non-Small Cell Lung Cancer

   Recruiting Phase 2 Verastem Started 2026Primary completion 2027-06 NCT07659782

   VS-7375

   Local testing confirmed KRAS G12D mutation (tissue required for confirmatory central testing)

   KRAS G12DNon-Small Cell Lung Cancer

3. A Phase II Study of GFH375 Combined With GFS202A or GFH276 Versus GFH375 in Patients With Previously Treated Locally Advanced Unresectable or Metastatic Pancreatic Cancer Harboring KRAS G12D Mutation

   Recruiting Phase 2 Genfleet Therapeutics Started 2026Primary completion 2028-08 NCT07784374

   VS-7375GFH276GFS202A

   …reviously Treated Locally Advanced Unresectable or Metastatic Pancreatic Cancer Harboring KRAS G12D Mutation

   KRAS G12DPancreatic Cancer

4. A Phase 2 Study of VS-7375 in Patients With KRAS G12D-Mutated Colorectal Cancer

   Recruiting Phase 2 Verastem Started 2026Primary completion 2027-06 NCT07659795

   VS-7375cetuximabpanitumumabmFOLFOX6

   Local testing confirmed KRAS G12D mutation (tissue required for confirmatory central testing)

   KRAS G12DColorectal Cancer

5. GFH375 Monotherapy and Combination Therapy as First-Line Treatment for Advanced KRAS G12D-Mutant Non-Small Cell Lung Cancer

   Not yet recruiting Phase 2 Genfleet Therapeutics Started 2026Primary completion 2027-04 NCT07554859

   VS-7375cetuximabpemetrexed

   Have a written report confirming KRAS G12D mutation positive.

   KRAS G12DNSCLC (Advanced Non-small Cell Lung Cancer)

6. A Phase 2 Study of VS-7375 in Patients With KRAS G12D-Mutated Pancreatic Cancer

   Recruiting Phase 2 Verastem Started 2026Primary completion 2027-06 NCT07644559

   VS-7375cetuximabpanitumumab

   Local testing confirmed KRAS G12D mutation (tissue required for confirmatory central testing)

   KRAS G12DPancreatic Ductal Adenocarcinoma (PDAC), G12D Mutated KRAS

7. A Phase 1/2 Study of VS-7375 in Patients With KRAS G12D-Mutated Solid Tumors

   Recruiting Phase 1/2 Verastem Started 2025Primary completion 2028-12 NCT07020221

   VS-7375cetuximabcarboplatinpemetrexedpembrolizumabgemcitabinenab-paclitaxeldefactinibmidazolamRepaglinide

   …cytologic evidence of locally advanced unresectable or metastatic solid tumor harboring a KRAS G12D mutation.

   KRAS G12DPancreatic Ductal Adenocarcinoma, Non Small Cell Lung Cancer, Colorectal Cancer, Solid Tumor, Adult

8. A Study of GFH375 Combined With Cetuximab or Chemotherapy in Participants With Solid Tumors Harboring KRAS G12D Mutation

   Recruiting Phase 1/2 Genfleet Therapeutics Started 2025Primary completion 2027-07 NCT07259590

   VS-7375cetuximabpaclitaxelgemcitabine

   …or cytologically confirmed locally advanced unresectable or metastatic solid tumors, with KRAS G12D mutation.

   KRAS G12DAdvanced Solid Tumors Cancer, PDAC, CRC (Colorectal Cancer)

9. A Study of GFH375 in Patients With Advanced Solid Tumors With KRAS G12D Mutations

   Recruiting Phase 1/2 Genfleet Therapeutics Started 2024Primary completion 2028-07 NCT06500676

   VS-7375

   …h histologically or cytologically confirmed advanced or metastatic solid tumors harboring KRAS G12D mutation.

   KRAS G12DKRAS G12D Mutations, Advanced Solid Tumors

No trials match these filters.